Revvity, Inc. (NYSE:RVTY) Shares Sold by V Square Quantitative Management LLC

V Square Quantitative Management LLC lessened its stake in Revvity, Inc. (NYSE:RVTY) by 6.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,964 shares of the company’s stock after selling 137 shares during the quarter. V Square Quantitative Management LLC’s holdings in Revvity were worth $251,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. EdgePoint Investment Group Inc. purchased a new stake in Revvity during the second quarter worth $209,221,000. Jane Street Group LLC boosted its stake in shares of Revvity by 516.4% during the 1st quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock worth $47,601,000 after acquiring an additional 379,802 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in shares of Revvity by 18.5% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,126,271 shares of the company’s stock valued at $223,258,000 after acquiring an additional 332,632 shares during the period. Janus Henderson Group PLC increased its stake in shares of Revvity by 3.9% in the 1st quarter. Janus Henderson Group PLC now owns 5,664,528 shares of the company’s stock valued at $594,769,000 after purchasing an additional 210,100 shares in the last quarter. Finally, Coronation Fund Managers Ltd. raised its holdings in Revvity by 261.3% in the 1st quarter. Coronation Fund Managers Ltd. now owns 253,722 shares of the company’s stock worth $26,641,000 after purchasing an additional 183,490 shares during the period. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Price Performance

NYSE:RVTY opened at $119.67 on Monday. Revvity, Inc. has a one year low of $79.50 and a one year high of $128.15. The stock has a market cap of $14.77 billion, a PE ratio of 98.90, a P/E/G ratio of 3.35 and a beta of 1.05. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. The stock has a 50 day moving average price of $121.61 and a 200 day moving average price of $113.13.

Revvity (NYSE:RVTY) last issued its earnings results on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. The business had revenue of $691.70 million during the quarter, compared to the consensus estimate of $690.33 million. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same period last year, the company earned $1.21 EPS. Equities research analysts expect that Revvity, Inc. will post 4.75 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.28 annualized dividend and a yield of 0.23%. Revvity’s payout ratio is 23.14%.

Insider Activity

In other news, insider Tajinder S. Vohra sold 2,153 shares of Revvity stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the sale, the insider now owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the transaction, the insider now directly owns 23,960 shares in the company, valued at approximately $2,925,276.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Tajinder S. Vohra sold 2,154 shares of the business’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the sale, the insider now owns 19,652 shares in the company, valued at approximately $2,392,237.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,807 shares of company stock valued at $937,576 in the last 90 days. Company insiders own 0.60% of the company’s stock.

Analyst Upgrades and Downgrades

RVTY has been the subject of a number of recent analyst reports. TD Cowen boosted their price objective on Revvity from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Bank of America boosted their price target on shares of Revvity from $118.00 to $127.00 and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Leerink Partnrs raised shares of Revvity to a “strong-buy” rating in a report on Monday, July 8th. Jefferies Financial Group lifted their target price on shares of Revvity from $115.00 to $125.00 and gave the company a “hold” rating in a research report on Monday, July 29th. Finally, Barclays upgraded shares of Revvity from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $140.00 in a research report on Tuesday, October 15th. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Revvity has a consensus rating of “Moderate Buy” and a consensus target price of $127.20.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.